HighTide Therapeutics Company Description

HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China.

Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis (MASH); in phase II clinical trial to treat severe hypertriglyceridemia; and in phase II clinical trial to treat primary sclerosing cholangitis, as well as in phase II clinical trial to treat primary biliary cholangitis.

The company is also developing HTD4010, a polypeptide drug, which is in phase I clinical trial for the treatment of alcoholic hepatitis; HTD1804 that is in preclinical trial to treat obesity; HTD1805, a multifunctional small molecule drug, which is in preclinical trial for the treatment of metabolic diseases; HTF1057 a preclinical-stage a drug candidate for the treatment of neurodegenerative diseases; HTF1037 a preclinical-stage for the treatment of obesity and comorbidities; and HTD2802 that is in preclinical trial for treating inflammatory bowel disease.

HighTide Therapeutics, Inc. was founded in 2011 and is headquartered in Shenzhen, China.

HighTide Therapeutics, Inc.

Country	Cayman Islands
Founded	2011
Industry	Biotechnology
Sector	Healthcare
Employees	57
CEO	Liping Liu

Contact Details

Address: Shenzhen-Hong Kong Shenzhen, 518112 China
Phone	86 755 2662 6253
Website	hightidetx.com

Stock Details

Ticker Symbol	2511
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	KYG4568L1023
SIC Code	2836

Key Executives

Name	Position
Dr. Liping Liu	Chief Executive Officer and Chairwoman
Meng Yu	Deputy GM and Executive Director
Koon Yin Sim	Chief Financial Officer
Liping Gao	Joint Company Secretary and Investor Relations Director
Dr. Leigh Anne MacConell	Chief Development Officer
Pik Man Chu	Joint Company Secretary